John McCaffrey
Overview
Explore the profile of John McCaffrey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1514
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
James S, Jabakhanji S, Mehta R, McCaffrey J, Mairghani M, Bhatia D, et al.
Confl Health
. 2025 Jan;
19(1):2.
PMID: 39810247
Background: Humanitarian crises bring unique, and potentially growing challenges to people with type 1 diabetes (T1D). We aimed to determine, in youth with T1D (mean age (± 1SD) 0-17.9 years)...
2.
Jabakhanji S, Ogungbe O, Angell S, Appel L, Byrne D, Mehta R, et al.
BMJ Open
. 2024 Jan;
14(1):e074443.
PMID: 38262656
Introduction: The COVID-19 pandemic significantly disrupted primary healthcare globally, with particular impacts on diabetes and hypertension care. This review will examine the impact of pandemic disruptions of diabetes and hypertension...
3.
Kieran R, Mitchell T, Fazari A, Chinoy A, Moloney C, McCaffrey J
J Oncol Pharm Pract
. 2023 Aug;
30(6):977-982.
PMID: 37559385
Introduction: Fluorouracil (5FU) and capecitabine are metabolised by dihydropyrimidine dehydrogenase (DPD). Up to 9% of people have low levels of a working DPD enzyme and are at risk of severe...
4.
McCaffrey J, Hunter A
HRB Open Res
. 2023 Jun;
6:29.
PMID: 37361338
Background: Despite methodological improvements in clinical trial design and conduct more generally, methodological limitations persist in trials concerning mental health care. A qualitative Study Within A Trial (Qual-SWAT), embedded in...
5.
Sheill G, Brady L, Hayes B, Baird A, Guinan E, Vishwakarma R, et al.
Support Care Cancer
. 2023 Apr;
31(5):292.
PMID: 37086362
Purpose: All patients living with cancer, including those with metastatic cancer, are encouraged to be physically active. This paper examines the secondary endpoints of an aerobic exercise intervention for men...
6.
Sweeney C, Martin A, Stockler M, Begbie S, Cheung L, Chi K, et al.
Lancet Oncol
. 2023 Mar;
24(4):323-334.
PMID: 36990608
Background: The interim analysis of the ENZAMET trial of testosterone suppression plus either enzalutamide or standard nonsteroidal antiandrogen therapy showed an early overall survival benefit with enzalutamide. Here, we report...
7.
Stockler M, Martin A, Davis I, Dhillon H, Begbie S, Chi K, et al.
J Clin Oncol
. 2021 Dec;
40(8):837-846.
PMID: 34928708
Purpose: We previously reported that enzalutamide improved overall survival when added to standard of care in metastatic, hormone-sensitive prostate cancer. Here, we report its effects on aspects of health-related quality...
8.
Chew S, Kathryn Carroll H, Darwish W, Boychak O, Higgins M, McCaffrey J, et al.
Cancer Manag Res
. 2021 Nov;
13:8191-8198.
PMID: 34754239
Purpose: Around 30% of patients with breast cancer will develop brain metastases (BM). We sought to characterize the disease course, treatments and outcome for our patient cohort. Materials And Methods:...
9.
Hayes B, Brady L, Sheill G, Baird A, Guinan E, Stanfill B, et al.
Cancers (Basel)
. 2021 Sep;
13(18).
PMID: 34572916
Interactions between circulating tumour cells (CTCs) and platelets are thought to inhibit natural killer(NK)-cell-induced lysis. We attempted to correlate CTC numbers in men with advanced prostate cancer with platelet counts...
10.
McDermott R, Greene J, McCaffrey J, Parker I, Helanova S, Baird A, et al.
Ther Adv Med Oncol
. 2021 Sep;
13:17588359211042691.
PMID: 34512801
Background: Radium-223 and enzalutamide are approved agents for patients with metastatic castration-resistant prostate cancer (mCRPC). Combining radium-223 and enzalutamide to improve outcomes is of clinical interest due to their differing...